Treatments tailored to specific causes of myocarditis, guided by endomyocardial biopsy, may improve clinical outcomes when added to established heart failure therapies.
Tailored treatments based on specific causes of myocarditis, guided by endomyocardial biopsy, may improve clinical outcomes in adults with inflammatory cardiomyopathies.
Myocarditis is generally a mild and self-limited consequence of systemic infection of cardiotropic viruses. However, patients can develop a temporary or permanent impairment of cardiac function including acute cardiomyopathy with hemodynamic compromise or severe arrhythmias. In this setting, specific causes of inflammation are associated with variable risks of death and transplantation. Recent translational studies suggest that treatments tailored to specific causes of myocarditis may impact clinical outcomes when added to guideline-directed medical care. This review summarizes recent advances in translational research that influence the utility of endomyocardial biopsy for the management of inflammatory cardiomyopathies. Emerging therapies for myocarditis based on these mechanistic hypotheses are entering clinical trials and may add to the benefits of established heart failure treatment.
Tschöpe et al. (Thu,) conducted a review in Myocarditis-Related Cardiomyopathy. Endomyocardial biopsy-guided tailored treatments was evaluated. Treatments tailored to specific causes of myocarditis, guided by endomyocardial biopsy, may improve clinical outcomes when added to established heart failure therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: